Penumbra (PEN) Cash from Financing Activities (2014 - 2026)
Penumbra's (PEN) quarterly Cash from Financing Activities came in at -$1.9 million in Q1 2026, down 170.42% year-on-year from $2.7 million in Q1 2025, and down 137.71% on a QoQ basis from $5.1 million in Q4 2025.
Penumbra (PEN) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Cash from Financing Activities data on file, last reported at -$1.9 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 170.42% year-over-year to -$1.9 million in Q1 2026; TTM through Mar 2026 was $21.9 million, a 126.25% increase from a year earlier, with the FY2025 full-year figure at $26.5 million, up 130.49% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$1.9 million, down from $5.1 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for PEN reached as high as $14.8 million in Q2 2025 and fell as low as -$100.6 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged -$2.0 million across 5 years, with a median of $4.0 million in 2025.
- Across the five-year window, Cash from Financing Activities slumped 47531.13% in 2024 and soared 441.06% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $5.7 million in 2022, then gained by 3.24% to $5.9 million in 2023, then grew by 2.48% to $6.1 million in 2024, then decreased by 16.66% to $5.1 million in 2025, then slumped by 137.71% to -$1.9 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$1.9 million in Q1 2026, $5.1 million in Q4 2025, and $4.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | -1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.91 Mn |
| Mar 31, 2026 | -1.91 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | 14.82 Mn |
| Jun 30, 2025 | 14.82 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Sep 30, 2024 | -100.55 Mn |
| Sep 30, 2024 | -100.55 Mn |
| Jun 30, 2024 | 8.27 Mn |
| Jun 30, 2024 | 8.27 Mn |
| Mar 31, 2024 | -794,000.00 |
| Mar 31, 2024 | -794,000.00 |
| Dec 31, 2023 | 5.92 Mn |
| Dec 31, 2023 | 5.92 Mn |